Current Perceptions of the Epidemiology of Atrial Fibrillation
Section snippets
Incidence, prevalence, and secular trends
Atrial fibrillation (AF) is a common, growing, and serious cardiac rhythm disturbance that is responsible for considerable morbidity and mortality in the population. The currently diagnosed estimate of 2.3 million people in the United States with it is expected to increase to 5.6 million by 2050. Its prevalence doubles with each decade of age, reaching almost 9% at the age of 80 to 89 years. Its population prevalence has reached epidemic proportions. This doubling with each decade of age occurs
Cardiovascular risk factors
Based on Framingham Study data, men have a 1.5-fold age- and risk factor–adjusted greater risk for AF than women. Of the standard cardiovascular risk factors, hypertension, diabetes, and obesity are the significant independent AF predictors. Because of its greater prevalence, hypertension is responsible for more AF in the population (14%) than any other risk factor (Table 2).2 Cigarette smoking was a significant risk factor in women adjusting only for age (odds ratio [OR] = 1.4) but was just
Cardiovascular conditions
Persons who develop AF usually are elderly and more likely than persons of the same age to have predisposing cardiac abnormalities.2, 5 Adjusting for cardiovascular risk factors, valvular heart disease, myocardial infarction, and heart failure substantially increases AF occurrence. Echocardiographic predictors of AF include left atrial enlargement, LV fractional shortening, LV wall thickness, and mitral annular calcification, offering prognostic information for AF beyond traditional clinical
Echocardiographic abnormalities
Echocardiographic enlargement of the left atrial dimension and abnormal mitral or aortic valve function were each associated independently with increased prevalence and incidence of AF in the Cardiovascular Health Study.1, 11 In the Framingham Study, echocardiographic predictors of AF include left atrial enlargement (39% increase in risk per 5-mm increment), LV fractional shortening (34% per 5% decrement), and LV wall thickness (28% per 4-mm increment) (Table 4). These echocardiographic
Clinical manifestations
AF can cause palpitations, fatigue, lightheadedness, and exertional dyspnea by precipitating myocardial decompensation. When there is underlying coronary disease, it can bring on or aggravate angina because of an often associated rapid heart rate. AF is often undetected, however, because of lack of symptoms it often is first detected by routine ECG examination in the course of a myocardial infarction or stroke, on implanted pacemakers, or on ambulatory ECG monitoring.
AF was diagnosed
Prognosis
AF is associated with an increased long-term risk for stroke, heart failure, and all-cause mortality, particularly in women.28 The doubled mortality rate of patients who have AF is linked to the severity of the underlying heart disease.29, 30, 31 Approximately two thirds of the 3.7% mortality over 8.6 months in the Activité Liberale la Fibrillation Auriculaire study was attributed to cardiovascular causes.32 AF also independently predicts excess mortality and an increased incidence of embolic
Public health burden and cost
AF, first described in 1909, has acquired increasing clinical and public health importance because of the expanding elderly population containing vulnerable candidates.47 Data from a National Hospital Discharge Survey indicate that hospital admissions resulting from AF increased two- to threefold from 1985 to 1999. During this period, hospitalizations listing AF increased from fewer than 800,000 to more than 2 million, predominantly in the elderly and men. Coyne and colleagues,49 assessing
Thyroid disease
For decades, hyperthyroidism has been an undisputed condition predisposing to AF. The prevalence of AF reported in patients at the time of diagnosis of overt hyperthyroidism varies from 2% to 30%.51, 52, 53 Approximately 10% to 15% of persons who have overt hyperthyroid disease with AF are reported to have an arterial embolic event.54, 55, 56 Studies also suggest that subclinical abnormalities of thyroid-stimulating hormone have detrimental effects on the cardiovascular system.57 Although AF is
Novel risk factors
Many novel modifiable and nonmodifiable risk factors for AF have been identified. These include reduced vascular compliance, atherosclerosis, insulin resistance, environmental factors, inflammatory markers, the obesity-induced metabolic syndrome, thrombogenic tendencies, sleep apnea, decreased arterial compliance, left atrial volume, diastolic dysfunction, and natriuretic peptides. There is emerging evidence that genetic variation also contributes to the risk for AF.
An inflammatory contribution
Genetic influences
Alleged genetically determined risk factors, such as blood pressure, obesity, and greater stature, predispose to AF. It is uncertain how these constitutional factors promote AF, but metabolic disorders and genetic factors may be implicated. A familial occurrence of AF has been recognized but is considered uncommon. The Framingham Study confirmed that observed parental AF increases its risk for offspring two- to threefold after excluding persons with predisposing conditions. This observation
Multivariable risk assessment
Multivariable risk assessment for stroke in patients who have AF is desirable for selecting those who most and least need aggressive anticoagulant therapy. The number needed to treat to prevent one event is inversely related to the level of risk; thus, estimating the risk for stroke for individual patients with AF is crucial for the decision to prescribe anticoagulation therapy. The threshold risk warranting anticoagulation remains controversial, however. Patients who have a stroke risk of 2%
Summary
We are faced with a burgeoning epidemic of AF, which urgently demands improved prevention and treatment of this condition and its cardiovascular substrate. AF and the left atrial enlargement associated with it are likely direct causes of embolic stroke, requiring early detection and treatment. Targeted multivariable profile screening to detect persons who are likely candidates for AF is needed.
Disappointing results of therapy to suppress or eliminate the rhythm disturbance have justifiably
References (83)
- et al.
Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates
Am J Cardiol
(1998) Etiology and complications of atrial fibrillatíon: insights from pathology studies
Am J Cardiol
(1998)- et al.
Atrial and ventricular arrhythmias in asymptomatic elderly subjects. Correlation with left atrial size and left ventricular mass
Am Heart J
(1990) - et al.
Pathology of the senescent heart: anatomic observations on 237 autopsy studies of patients 90 to 105 years old
Mayo Clin Proc
(1988) - et al.
Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study)
Am J Cardiol
(1994) - et al.
Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the epidemiology, practice, outcomes, and costs of heart failure (EPOCH) study
J Am Coll Cardiol
(2004) - et al.
The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades
J Am Coll Cardiol
(2003) - et al.
Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study
Am J Cardiol
(2004) - et al.
Mitral annular calcification is a predictor for incident atrial fibrillation
Atherosclerosis
(2004) - et al.
Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care
J Am Coll Cardiol
(2004)
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study
Am J Med
Coronary heart disease and atrial fibrillation: the Framingham Study
Am Heart J
The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up study
Am J Med
Risk of stroke in non-rheumatic atrial fibrillation
Lancet
Secular trends in the prevalence of atrial fibrillation: the Framingham study
Am Heart J
Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States
Value Health
Thyrotoxicosis, atrial fibrillation and embolism revisited
Am Heart J
Association of obesity with left ventricular remodeling and diastolic dysfunction in patients without coronary artery disease
Am J Cardiol
The relationship between stature and the prevalence of atrial fibrillation in patients with left ventricular dysfunction
J Am Coll Cardiol
Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women
J Am Coll Cardiol
Familial atrial fibrillation is a genetically heterogeneous disorder
J Am Coll Cardiol
Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience
J Am Coll Cardiol
Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation?
J Am Coll Cardiol
Trends in anticoagulation for atrial fibrillation in the U.S.: an analysis of the national ambulatory medical care survey database
J Am Coll Cardiol
Incidence of and risk factors for atrial fibrillation in older adults
Circulation
Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study
J Am Med Assoc
Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications
Arch Intern Med
Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
J Am Med Assoc
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Circulation
Epidemiology and significance of atrial fibrillation
Am J Cardiol
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study
Circulation
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study
Eur Heart J
Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart study
Circulation
Obesity and risk of new-onset atrial fibrillation after cardiac surgery
Circulation
Risk of new-onset atrial fibrillation in relation to body mass index
Arch Intern Med
High prevalence of paroxysmal atrial fibrillation and/or atrial flutter in metabolic syndrome
Circ J
Obesity and the risk of new onset atrial fibrillation
JAMA
Pulse pressure and risk of new onset atrial fibrillation
J Am Med Assoc
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension
J Am Med Assoc
Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study
Circulation
Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study
J Am Med Assoc
Cited by (115)
Bone morphogenetic protein 10 and atrial fibrillation
2024, IJC Heart and VasculatureUpdates in the management of atrial fibrillation: Emerging therapies and treatment
2024, Disease-a-MonthThe Blinding Period Following Ablation Therapy for Atrial Fibrillation: Proarrhythmic and Antiarrhythmic Pathophysiological Mechanisms
2021, JACC: Clinical ElectrophysiologyCardiothyreosis: Prevalence and risk factors
2019, Annales d'EndocrinologieCitation Excerpt :Our study confirms that age is independently associated with a higher risk of AF and CHF in hyperthyroid patients [8,18–22]. Actually, the risks of AF and CHF increase with age regardless of the presence of hyperthyroidism or not [23,24]. These risks are however higher in case of hyperthyroidism [20,22].
A version of this article originally appeared in Medical Clinics of North America, volume 92, issue 1.
Funding for this study was provided by grants N01-HC 25195, RO1 HL076784, 1R01 AG028321, and 6R01-NS 17950.